TPVI offers a ray of hope for children with Pulmonic Valve disease
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
The 50-bed hospital is positioned to address complexities specific to women and children, going beyond a birthing facility
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
It has been built at a cost of Rs 19.5 crores through internal accruals of the Malabar Institute of Medical Sciences (MIMS)
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
The trial will be conducted across 10 sites in India
Subscribe To Our Newsletter & Stay Updated